What's Happening?
STORM Therapeutics, a Cambridge-based biotech company, has raised $56 million in a Series C funding round to support the development of its RNA-targeting cancer drug, STC-15. The drug, which targets RNA modifications, is in Phase 2 trials for treating
sarcomas. The funding will help advance clinical trials and explore additional oncology indications. STC-15 has shown promise in early trials, demonstrating tumor regression in various sarcoma subtypes.
Why It's Important?
The funding boost for STORM Therapeutics highlights the growing interest in RNA-targeting therapies, which offer a novel approach to cancer treatment. If successful, STC-15 could provide new treatment options for sarcomas, which are challenging to treat with existing therapies. The investment from major pharmaceutical companies underscores the potential of RNA-targeting drugs to address unmet needs in oncology, potentially leading to breakthroughs in cancer treatment.
